Amy A. Lemke
NorthShore University HealthSystem
Publications 6
#1Rachel Mills (Duke University)H-Index: 11
#2Jennifer N. Eichmeyer (BSU: Boise State University)
Last.Amy A. Lemke (NorthShore University HealthSystem)H-Index: 4
view all 7 authors...
Purpose of Review Pharmacogenomics is an evolving area in precision medicine that aims to identify patients who have variable drug response, detect those at risk for developing adverse events, and guide drug dosing. Guidelines for optimization of PGx testing are available for a number of drug-gene pairs, and evidence supporting the clinical utility of this service is growing in specific patient contexts. This report reviews a variety of patient care situations in which evidence is emerging to sh...
#1Amy A. Lemke (NorthShore University HealthSystem)H-Index: 4
#2Peter J. Hulick (NorthShore University HealthSystem)H-Index: 17
Last.Henry M. Dunnenberger (NorthShore University HealthSystem)H-Index: 12
view all 8 authors...
4 CitationsSource
#1Heather Zierhut (UMN: University of Minnesota)H-Index: 9
#2Colleen A. Campbell (UI: University of Iowa)H-Index: 12
Last.Jeffrey R. Bishop (UMN: University of Minnesota)H-Index: 25
view all 6 authors...
Increased use of pharmacogenomic (PGx) testing in the clinical setting has revealed a number of challenges to the provision of this service. PGx is an important component of precision medicine which brings together the fields of genetics and clinical pharmacology. A model that incorporates a multi-disciplinary approach to implementation and information delivery may be the most beneficial to patients and providers. In this review, translational considerations in the provision of PGx testing and c...
8 CitationsSource
#1Amy A. Lemke (NorthShore University HealthSystem)H-Index: 4
#2Christina G. Selkirk (NorthShore University HealthSystem)H-Index: 8
Last.Henry M. Dunnenberger (NorthShore University HealthSystem)H-Index: 12
view all 7 authors...
Aim: To explore primary care physicians’ views of the utility and delivery of direct access to pharmacogenomics (PGx) testing in a community health system. Methods: This descriptive study assessed the perspectives of 15 healthcare providers utilizing qualitative individual interviews. Results: Three main themes emerged: perceived value and utility of PGx testing; challenges to implementation in practice; and provider as well as patient needs. Conclusion: While providers in this study viewed bene...
12 CitationsSource
#1David Cella (NorthShore University HealthSystem)H-Index: 130
#2Chanita Hughes (Georgetown University)H-Index: 24
Last.Caryn Lerman (Georgetown University)H-Index: 93
view all 10 authors...
The Multidimensional Impact of Cancer Risk Assessment (MICRA) is a new tool to measure the specific impact of result disclosure after genetic testing. The authors compared its performance with that of questionnaires measuring general and cancer-specific distress. Participants (158 women) responded 1 month after they received genetic test results. The women were divided into 4 standard clinical test result groups: BRCAI/2 positive, BRCA1/2 negative, panel negative, and true negative. Factor analy...
153 CitationsSource
#1Amy A. Lemke (NorthShore University HealthSystem)H-Index: 4
#2Sheela Dayal (U of C: University of Chicago)H-Index: 1
Last.Leslie J. Geibel (NorthShore University HealthSystem)H-Index: 1
view all 3 authors...
In the United States, access to genetic education and services is not equally available to all segments of the population, especially to women of minority backgrounds and low incomes. In response to this issue, the Preconception Genetic Health Education Program (PGHEP) was implemented in September of 1993 at the Woodlawn Maternal and Child Health Center in south side Chicago. The goal of this program is to provide access to genetic services to a previously underserved population. Women attending...
3 CitationsSource